Cogent Biosciences Inc. Common Stock (COGT)
Stock · NASDAQ · Health Care
$29.52as of 10/16/2026
Price chart
Active signals
COGT Signal Track Record
How signals performed across all stocks →What COGT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | -1.1% | 49% | September 8, 2026 |
| Bollinger Band Breakout | 24 | +4.9% | 54% | August 4, 2026 |
| Bollinger Band Breakdown | 21 | -1.9% | 43% | September 18, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -6.0% | 33% | August 24, 2026 |
| Any 20-session window (baseline) | +1.2% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About COGT
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations i…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 258
- Website
- www.cogentbio.com/
Fundamentals
- 1-day range
- $27.74$29.05
- Market cap
- $7.14B
- P/E (trailing)
- —
- P/E (forward)
- -25.32
- EPS (trailing)
- $-2.44
- Dividend yield
- —
- Beta
- 0.32
- Avg. volume
- 1.93M
- Dividend pay date
- November 9, 2020
How Cogent Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2019 annual results
Source: 10-K filed Mar 26, 2020 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
Cogent Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- COGTCogent Biosciences Inc. Common Stock$29.52▲ 0.03%Market cap $7.14BP/E —$13.78$43.73
- TGTXTG Therapeutics Inc. Common Stock$53.97▼ 3.62%Market cap $7.59BP/E 19.42$26.76$59.3
- RYTMRhythm Pharmaceuticals Inc. Common Stock$86.17▼ 2.05%Market cap $7.72BP/E —$74.5$122.2
- LQDALiquidia Corporation Common Stock$34.35▼ 1.24%Market cap $7.95BP/E 22.46$21.94$93.61
- BLTEBelite Bio Inc American Depositary Shares$142.78▼ 6.45%Market cap $6.32BP/E —$78.71$200
- ERASErasca Inc. Common Stock$13.39▼ 9.95%Market cap $6.25BP/E —$2.11$24.28
- XENEXenon Pharmaceuticals Inc. Common Shares$33.49▼ 2.45%Market cap $6.24BP/E —$33.52$72.66
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| COGT Cogent Biosciences Inc. Common Stock | $7.14B | — | $29.52 | ▲ 0.03% | $13.78$43.73 |
| TGTX TG Therapeutics Inc. Common Stock | $7.59B | 19.42 | $53.97 | ▼ 3.62% | $26.76$59.3 |
| RYTM Rhythm Pharmaceuticals Inc. Common Stock | $7.72B | — | $86.17 | ▼ 2.05% | $74.5$122.2 |
| LQDA Liquidia Corporation Common Stock | $7.95B | 22.46 | $34.35 | ▼ 1.24% | $21.94$93.61 |
| BLTE Belite Bio Inc American Depositary Shares | $6.32B | — | $142.78 | ▼ 6.45% | $78.71$200 |
| ERAS Erasca Inc. Common Stock | $6.25B | — | $13.39 | ▼ 9.95% | $2.11$24.28 |
| XENE Xenon Pharmaceuticals Inc. Common Shares | $6.24B | — | $33.49 | ▼ 2.45% | $33.52$72.66 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 YearsBenzinga · 9/17/2026
- Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price TargetBenzinga · 9/16/2026
- Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)Yahoo · 9/15/2026
- HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price TargetBenzinga · 9/15/2026
- FDA Accepts Cogent Biosciences' NDA For Bezuclastinib In Patients With Advanced Systemic MastocytosisBenzinga · 9/15/2026
Insider Activity
Insider Actions →- Arlene Morris · August 27, 2026 · Option Exercise3.6K @ $2.52
- Arlene Morris · August 27, 2026 · Option Exercise41.9K @ $5.64
- Arlene Morris · August 27, 2026 · Sale3.2K @ $37.54
- Arlene Morris · August 27, 2026 · Sale42.3K @ $37.09
- Ferrante Karen Jean · July 1, 2026 · Grant627
- Arlene Morris · June 9, 2026 · Grant17.9K
- Shegog Todd · June 9, 2026 · Grant17.9K
- Ros Matthew · June 9, 2026 · Grant17.9K
- Harwin Peter Evan · June 9, 2026 · Grant17.9K
- CAIN CHRISTOPHER W. · June 9, 2026 · Grant17.9K
- Ferrante Karen Jean · June 9, 2026 · Grant17.9K
- Andrew R. Robbins · May 19, 2026 · Gift160.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 178.49M
- Total value held
- $6.60B
- Institutional holders
- 299
- Unknown23.12M
- Unknown16.05M
- Unknown9.04M
- Unknown6.89M
- Unknown5.97M
- Unknown5.66M
- Unknown5.50M
- Unknown5.46M
- Unknown4.95M
- Unknown4.43M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Cogent Biosciences: Long-term performance review published
Benzinga published an article analyzing the value of a $1,000 investment in Cogent Biosciences made five years ago. This piece focuses on historical returns rather than new corporate developments or immediate market catalysts. The stock is currently trading near its 52-week low, with technical indicators showing recent downward pressure.
Cogent Biosciences: Long-term performance review published. Benzinga published an article analyzing the value of a $1,000 investment in Cogent Biosciences made five years ago. This piece focuses on historical returns rather than new corporate developments or immediate market catalysts. The stock is currently trading near its 52-week low, with technical indicators showing recent downward pressure.